<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide and <z:chebi fb="0" ids="2038">azacitidine</z:chebi> each have activity in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this multicenter, phase 2 expansion trial was to determine the efficacy and safety of combination therapy with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (75 mg/m(2)/d for 5 days) and lenalidomide (10 mg/d for 21 days; 28-day cycle) in patients with higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Among 36 patients enrolled (18 phase 1, 18 phase 2), median age was 68 years (range, 47-78 years) and follow-up was 12 months (range, 3-55 years) </plain></SENT>
<SENT sid="3" pm="."><plain>IPSS categories included intermediate-1 (n = 5 patients with excess blasts), intermediate-2 (20), and high (11) </plain></SENT>
<SENT sid="4" pm="."><plain>Common grade 3/4 nonhematologic adverse events included febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (22% of patients), other <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (11%), pulmonary (11%), cardiac (11%), constitutional (11%), and dermatologic (11%) </plain></SENT>
<SENT sid="5" pm="."><plain>The overall response rate (per modified <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> International Working Group criteria) was 72%: 16 patients (44%) achieved a complete response (CR), and 10 (28%) had hematologic improvement </plain></SENT>
<SENT sid="6" pm="."><plain>Median CR duration was 17+ months (range, 3-39+); median overall survival was 37+ months (range, 7-55+) for CR patients, and 13.6 months for the entire cohort (range, 3-55) </plain></SENT>
<SENT sid="7" pm="."><plain>TET2/DNMT3A/IDH1/2 mutational status was associated with response in a limited number of patients </plain></SENT>
<SENT sid="8" pm="."><plain>The lenalidomide/<z:chebi fb="0" ids="2038">azacitidine</z:chebi> combination is well-tolerated and highly active in treating greater-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>